In order to further investigate the role of p53 in the effects of the aurora kinase inhibitors on the viability of the neuroblastoma cell lines, we combined tozasertib with the p53 activator nutlin-3 that interferes with the interaction of p53 and its endogenous inhibitor MDM2 through MDM2 binding [41]. This evidence concerns the gene TP53 and neuroblastoma.